Form 4: Immunovant CFO Acquires Stock Options and RSUs

Immunovant's Chief Financial Officer, Tiago Girao, acquired stock options and restricted stock units (RSUs) on April 7, 2026, as detailed in a Form 4 filing.

Summary

• Tiago Girao, Chief Financial Officer of Immunovant, Inc., acquired securities on April 7, 2026.
• The acquisition included 64,968 shares of Common Stock, acquired at $0 price, bringing the total beneficial ownership to 273,356 shares.
• Additionally, 94,002 stock options were acquired, with an exercise price of $24.61, and are set to expire on April 7, 2036.
• These options and Restricted Stock Units (RSUs) were granted under the company's 2019 Equity Incentive Plan.
• The RSUs vest 25% on April 1, 2027, with the remainder vesting quarterly thereafter.
• The stock options vest 25% on April 1, 2027, with the remainder vesting monthly thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it details routine equity grants to a key executive, which is standard practice and can signal executive commitment, but does not provide new financial performance data.

Positives

• The Chief Financial Officer's acquisition of stock options and RSUs may indicate confidence in the company's future performance.
• The acquisition of 64,968 shares of common stock at no cost suggests a form of equity compensation or grant.
• The grant of 94,002 stock options provides potential upside for the CFO tied to the company's stock performance.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• Vesting schedules for RSUs and stock options are subject to the Reporting Person's continuous service to the Issuer, implying a risk of forfeiture if service is not maintained.
• The exercise price of stock options ($24.61) means that the value of these options is dependent on the stock price exceeding this threshold.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a long-term incentive structure tied to continued employment and company performance, with significant portions vesting in 2027 and thereafter.

Industry Context

StockSavvy.ai notes that the granting of stock options and RSUs to key executives like the CFO is a common practice in the biotechnology and pharmaceutical industry to align executive interests with shareholder value and incentivize long-term growth.

Stakeholder Impact

• Shareholders: The acquisition of equity by the CFO can be seen as a positive signal of commitment, potentially aligning executive and shareholder interests.
• Employees: The existence of equity incentive plans, as evidenced by these grants, suggests a broader framework for employee compensation and retention.
• Management: The CFO's compensation is directly tied to the company's stock performance through these options and RSUs.

Next Steps

• Continuous service by Tiago Girao to Immunovant, Inc. to meet vesting requirements for RSUs and stock options.
• Vesting of RSUs and stock options according to the specified schedules (25% on April 1, 2027, followed by quarterly/monthly installments).

Key Dates

Keywords

Immunovant, IMVT, Form 4, Insider Trading, Stock Options, RSUs, Equity Incentive Plan, Tiago Girao, Chief Financial Officer, Securities Acquisition